Harm Westdorp and Jeroen Creemers (group of Jolanda de Vries) reported in the Journal for Immunotherapy of Cancer that vaccination with blood-derived myeloid dendritic cells (cDC2) and/or plasmacytoid dendritic cells (pDC) induced functional tumor antigen-specific immune responses in patients with castration-resistant prostate cancer. Patients harboring functional antigen-specific T cells showed a significantly increased median radiographic progression-free survival and might have an overall survival benefit compared to patients without these cells. Immunotherapy with these blood-derived DC subsets was feasible and safe.
This immune correlate might be indicative for a beneficial response to DC vaccination and opens up new opportunities for future immunotherapy trials with the intention of long-term cancer control.
Link to the open access version of the paper:
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer